DUBLIN, March 12, 2018 /PRNewswire/ --
The "Global Bacterial Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Bacterial Partnering 2012 to 2018 provides the full collection of Bacterial disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Bacterial disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Bacterial deals.
The report presents financial deal terms values for Bacterial deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Bacterial partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Bacterial partnering and dealmaking since 2012.
The report includes deals for the following indications:
Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Bacterial dealmaking
2.1. Introduction
2.2. Bacterial partnering over the years
2.3. Bacterial partnering by deal type
2.4. Bacterial partnering by industry sector
2.5. Bacterial partnering by stage of development
2.6. Bacterial partnering by technology type
2.7. Bacterial partnering by therapeutic indication
Chapter 3 -Financial deal terms for Bacterial partnering
3.1. Introduction
3.2. Disclosed financials terms for Bacterial partnering
3.3. Bacterial partnering headline values
3.4. Bacterial deal upfront payments
3.5. Bacterial deal milestone payments
3.6. Bacterial royalty rates
Chapter 4 - Leading Bacterial deals and dealmakers
4.1. Introduction
4.2. Most active in Bacterial partnering
4.3. List of most active dealmakers in Bacterial
4.4. Top Bacterial deals by value
Chapter 5 - Bacterial contract document directory
5.1. Introduction
5.2. Bacterial partnering deals where contract document available
Chapter 6 - Bacterial dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Bacterial therapeutic target
Appendices
Appendix 1 - Directory of Bacterial deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Bacterial deals by deal type 2012 to 2018
Appendix 3 - Directory of Bacterial deals by stage of development 2012 to 2018
Appendix 4 - Directory of Bacterial deals by technology type 2012 to 2018
For more information about this report visit
https://www.researchandmarkets.com/research/s92n98/global_bacterial?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article